The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.
本发明涉及替代的氮杂
吲哚异
异喹啉化合物,特别是7-、8-、9- 和10-氮杂
吲哚异
异喹啉化合物,它们是拓扑异构酶I的
抑制剂,以及用于合成它们的过程和中间体,这些化合物的药物组合物,以及在癌症治疗中使用它们的方法。